| __timestamp | Biogen Inc. | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 7890000 |
| Thursday, January 1, 2015 | 2113100000 | 14456000 |
| Friday, January 1, 2016 | 1947900000 | 19218000 |
| Sunday, January 1, 2017 | 1935500000 | 27986000 |
| Monday, January 1, 2018 | 2106300000 | 47928000 |
| Tuesday, January 1, 2019 | 2374700000 | 96388000 |
| Wednesday, January 1, 2020 | 2504500000 | 157743000 |
| Friday, January 1, 2021 | 2674300000 | 195293000 |
| Saturday, January 1, 2022 | 2403600000 | 237374000 |
| Sunday, January 1, 2023 | 2549700000 | 295141000 |
| Monday, January 1, 2024 | 2403700000 | 359272000 |
Data in motion
In the competitive world of biotechnology, understanding financial trends is crucial. Over the past decade, Biogen Inc. and Blueprint Medicines Corporation have shown contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Biogen, a stalwart in the industry, has consistently maintained high SG&A expenses, peaking in 2021 with a 38% increase from 2014. In contrast, Blueprint Medicines, a rising star, has seen its SG&A expenses skyrocket by over 3,600% since 2014, reflecting its aggressive growth strategy. This divergence highlights the different stages and strategies of these companies. While Biogen focuses on sustaining its market position, Blueprint is investing heavily in expansion. These insights offer a glimpse into the strategic priorities shaping the biotech landscape today.
Pfizer Inc. and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Biogen Inc. and BeiGene, Ltd.
Biogen Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Biogen Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Biogen Inc. vs Novavax, Inc.
Biogen Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Insmed Incorporated and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Madrigal Pharmaceuticals, Inc.
Blueprint Medicines Corporation and MorphoSys AG: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Blueprint Medicines Corporation or Galapagos NV
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.